1. Search Result
Search Result
Results for "

activated platelet-rich plasma

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P0074
    GPRP
    3 Publications Verification

    Gly-Pro-Arg-Pro; Pefa 6003

    Thrombin Cardiovascular Disease
    GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of thrombin onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .
    GPRP
  • HY-Y1094

    Chloro(1,5-cyclooctadiene)rhodium(I) dimer

    Biochemical Assay Reagents Cardiovascular Disease
    [Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) is a rhodium (I) organometallic dimer complex. [Rh(cod)Cl]2 can inhibit platelet-activating factor-mediated platelet aggregation with IC50 values of 5.2 and 43.3 μM in washed rabbit platelets and human platelet-rich plasmas. [Rh(cod)Cl]2 also can inhibit thrombin-, ADP (HY-W010918)- and collagen-induced aggregation with IC50 values of 16.7, 162 and 69.8 μM. [Rh(cod)Cl]2 can be used for the research of cardiovascular disease, such as thrombosis .
    [Rh(cod)Cl]2
  • HY-163341

    Protease Activated Receptor (PAR) Cardiovascular Disease
    PAR4 antagonist 1 (Compound 48) is a protease activated receptor 4 (PAR4) antagonist with an IC50 of 1.8 nM. PAR4 antagonist 1 has an IC50 of 2 nM against γ-thrombin-activated PAR4 in platelet-rich plasma (PRP). PAR4 antagonist 1 can be used in antithrombotic research .
    PAR4 antagonist 1
  • HY-128345

    Protease Activated Receptor (PAR) Cardiovascular Disease
    UDM-001651 is a potent, selective, and orally bioavailable protease-activated receptor 4 (PAR4) antagonist (IC50=4 nM; Kd=1.4 nM). UDM-001651 shows antiplatelet potency (IC50=25 nM) in a γ-thrombin-induced platelet-rich plasma aggregation assay (γ-Thr PRP) .
    UDM-001651
  • HY-19126

    Platelet-activating Factor Receptor (PAFR) Infection Cardiovascular Disease
    CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
    CL-184005
  • HY-107000

    Guanylate Cyclase NO Synthase Cardiovascular Disease
    RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen (HY-NP003)-induced platelet aggregation in platelet-rich plasma (PRP). RIG 200 may be used in research on antithrombus .
    RIG 200
  • HY-182418

    Platelet-activating Factor Receptor (PAFR) Cardiovascular Disease
    UR-11353 is a selective platelet activating factor (PAF) antagonist with long-lasting activity. UR-11353 inhibits PAF-induced platelet aggregation in rabbit platelet-rich plasma. UR-11353 inhibits PAF-induced hypotension in normotensive rats. UR-11353 protects against PAF-induced mortality in mice .
    UR-11353
  • HY-182625

    Platelet-activating Factor Receptor (PAFR) Others Inflammation/Immunology
    GS-1160-180 is a PAF receptor antagonist. GS-1160-180 competes with PAF for receptor binding, with no activity against collagen or adenosine diphosphate-induced platelet aggregation. GS-1160-180 can be used for research on asthma, anaphylactic shock, gastric ulceration, and transplant rejection .
    GS-1160-180

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: